{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"primary-hyperoxaluria-type-1","columns":[{"gene":"","key":"population-3e6e625bf703e1b61d68","label":"Hyperoxaluria, primary, type I","mondoId":"MONDO:0009823","onsetQualifier":null,"originColumnKey":"MONDO:0009823/OMIM:259900","originalViews":[{"key":"MONDO:0009823/OMIM:259900","label":"Hyperoxaluria, primary, type I","scopeLabel":"OMIM:259900","sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"recordKeys":["054900db6436cd10c935486ef3df88287fa0a978d386bfd20c8ae71ca1ab174d","07af6f00904a261712fcde80c2103eeee0baf8f8aa4ef501201429a4cb810b09","0ee4816ffc07ff368cc4c246b15ed1584a775f2c60fa8d8616bfac3f25e47569","1e62f7397bd9dcc044d8a807abae482d7bc68101763a7e47d462c3c039cacd21","39ef4fc0468c290acf363b10bd0fc8cd71bebac286c1038c7292cfa070eb8773","41c4033310c5c5b17009973bf0c2c4e536ec28b397b4eb4b159905df88fdf256","5482e2946aa410ffae8b12c6416dacab0aa1f65200d183a3f39f3b96d75ea285","5cd6562400518022108d9070cee1d4c9958e4d5518a348ce0bc66dabe463b198","67a866e72944b963e62a2fc0717197009c6508344d1505e707a500738e029e07","80ba6148cba3ed9c0a39a5e529a0b497bd90cc65fd32c9b9929754e0e0c4047c","94097ce1b89b89019ab09ec423819e9da27ea08cfcf56476eb78c56f8e3e38de","9a32a06948e0f9158aa6b30c4d22841b15c483eab6bcb8956fb38e2333995349","9c7743e0ad239784bf7dff7f5579d29ecb8329ff587808268aac6ad3cd8c94fe","ab79f110d18c2e722e1f2a6f1776c220bc1dd5f807ecdb9bbdb67a40cd1f3bc8","c94d7200dd54fcc293965121dfb1613de325a39b40797dfc2be8541360b9e88d","ccf55bc357db621ab9e761d8f5aa511ac18a44d63ed0c8661228ef9f218a01bf","cfaa1e7f3da8f46d5155ab7884acde746c1fb3fb341f4997241244f7d35d3ec2","d3c909b0dbe58e880bed7f6808297de19ade9c70b22a383faa787e55cf853696","d3db3b8e946bb368b403c3e1a655a1589befd49c1c620212767e6ddeacce38c9","d3ee045c75afcee13dd1b0676171034e8dd29cb5dd804e1f05813049e142b9a9","d7f11fb7a8e737c6589b066b5ab7d8e5735fbedef3768932b18c183a287f82a9","da2e0544db03cc3f4d4b0eebab26303d2e068ce298f1270247b25e7f36e14651","e25e722c40fefe8c70b05725c64f70acceb0508489c3f0a9c4c9bb62b639a317","e509a7adb7216565fac334d760d939876a400933c4f29d91f6a137d1161551f3","e837a9340b2583e869505a0dbd8725eed04c0d8bf2b26defe0df66a65af39893","ea952d01b08fcf2bf9bac8e9b40da2692ec425b37cf72531715daaa6f8e75568","edf6f03dd51a8a850b0a92b88a37885ef0f132713d1000b7a9c5742f8ca8310e","eeadf09b54ef2493d1140a56b660ceb168f10d0cc7ce746f1a47a7123be977cf"],"recordQualifiers":{},"scopeLabel":"OMIM:259900","sourceIds":["OMIM:259900"],"sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."},{"gene":"","key":"population-c20c6a38a305a04a30df","label":"Primary hyperoxaluria type 1","mondoId":"MONDO:0009823","onsetQualifier":null,"originColumnKey":"MONDO:0009823/ORPHA:93598","originalViews":[{"key":"MONDO:0009823/ORPHA:93598","label":"Primary hyperoxaluria type 1","scopeLabel":"ORPHA:93598","sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"recordKeys":["23aba4817b7b2a1bb073c7515da2e09c6d04778c9d635c4f492a596528d2215d","3a0f00099324a590e33d3dbdcbc21e73bc2479dec910b90db010731ffbcbfd45","4d4044a3ba47aba89d64f8d3cd87f6f98cc4b4cd97a4af8740124c19aa9ca135","4d6cea65fdb43ea4570103186e5ead118c565d81a5e032d9379d7137064b2171","4f8a154ee605a97085b3d150d3a7a814af1321173fce70e69af64d6c524e9d64","5936aa488f9fed457e56aa3004875c972fe721c756e98bb8895a064a0dd53c46","5c9f7257faac96eaffe0351e9461f3698fa95df9dc2357085735e6c232f7a304","678188c53461305c1af87c432fcd12fb98562207f784f4c4c8ecbcbc59a930c8","75628f5bc7bcae99e72a882046e6de45aaf98934c3cb02459b616a3334bf06fc","77a4e41c312866a5f6645517a9024ae0e5969efe8176643260235d549cb024f5","8a3fb56b34ed61c50033d41f4358d2ff13df9815d4187aa8bbf82f5f0d48dae5","938f83c8d28a370baac39bae1bc815c7436f2eebad2bf1bca10a828939509125","a37d1e2e85f4e0d9f255e13c6cc888525baea20b939da68635f114b4bfb520a3","bcf4ff6d9d6189ae5af4d4f02be527d876f9c198d657d4734f94829f139a32f6","d78fe3b713672c7971b030801e5e3072bbfa180f4915b613f91c3de773f5b477","daa42829d012fd35ba4d3c7bbaec04dc283c9abc21addac74d19e72b1a60bb43","e46f6286d15916ab71916c327bd692f08b32d33f4a8998de334ee5d1cf47019d","f9c1ab898489b8d994eb1652606496e6724b26efd850e1056a0243483216b2e5","fac1aa3ad7b4a11d6fa545c2cb7a9d19b0aed29795edcc9c27d93618f313b746"],"recordQualifiers":{},"scopeLabel":"ORPHA:93598","sourceIds":["ORPHA:93598"],"sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-3e6e625bf703e1b61d68","population-c20c6a38a305a04a30df"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0011021","HP:0001939","HP:0000164","HP:0000924","HP:0001063","HP:0001903","HP:0025324"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":6,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":47,"sourceGroups":{"omim":20,"orphanet":19,"published":8}},"features":[{"hpoId":"HP:0011021","label":"Abnormal circulating enzyme concentration","primary":true},{"hpoId":"HP:0001939","label":"Abnormality of metabolism/homeostasis","primary":true},{"hpoId":"HP:0000164","label":"Abnormality of the dentition","primary":true},{"hpoId":"HP:0000924","label":"Abnormality of the skeletal system","primary":true},{"hpoId":"HP:0001063","label":"Acrocyanosis","primary":true},{"hpoId":"HP:0001903","label":"Anemia","primary":true},{"hpoId":"HP:0025324","label":"Arterial occlusion","primary":true},{"hpoId":"HP:0002621","label":"Atherosclerosis","primary":false},{"hpoId":"HP:0001678","label":"Atrioventricular block","primary":false},{"hpoId":"HP:0002653","label":"Bone pain","primary":false},{"hpoId":"HP:0003761","label":"Calcinosis","primary":false},{"hpoId":"HP:0025520","label":"Calcinosis cutis","primary":false},{"hpoId":"HP:0008672","label":"Calcium oxalate nephrolithiasis","primary":false},{"hpoId":"HP:0011506","label":"Choroidal neovascularization","primary":false},{"hpoId":"HP:0000965","label":"Cutis marmorata","primary":false},{"hpoId":"HP:0012213","label":"Decreased glomerular filtration rate","primary":false},{"hpoId":"HP:0001944","label":"Dehydration","primary":false},{"hpoId":"HP:0100518","label":"Dysuria","primary":false},{"hpoId":"HP:6000431","label":"Elevated urinary glycolic acid level","primary":false},{"hpoId":"HP:6000702","label":"Elevated urinary glyoxylic acid level","primary":false},{"hpoId":"HP:0000805","label":"Enuresis","primary":false},{"hpoId":"HP:0001508","label":"Failure to thrive","primary":false},{"hpoId":"HP:0100758","label":"Gangrene","primary":false},{"hpoId":"HP:0000790","label":"Hematuria","primary":false},{"hpoId":"HP:0003159","label":"Hyperoxaluria","primary":false},{"hpoId":"HP:0011001","label":"Increased bone mineral density","primary":false},{"hpoId":"HP:0004417","label":"Intermittent claudication","primary":false},{"hpoId":"HP:0000787","label":"Kidney stone","primary":false},{"hpoId":"HP:0001942","label":"Metabolic acidosis","primary":false},{"hpoId":"HP:0000121","label":"Nephrocalcinosis","primary":false},{"hpoId":"HP:0000648","label":"Optic atrophy","primary":false},{"hpoId":"HP:0001138","label":"Optic neuropathy","primary":false},{"hpoId":"HP:0002756","label":"Pathologic fracture","primary":false},{"hpoId":"HP:0004950","label":"Peripheral arterial stenosis","primary":false},{"hpoId":"HP:0009830","label":"Peripheral neuropathy","primary":false},{"hpoId":"HP:0030880","label":"Raynaud phenomenon","primary":false},{"hpoId":"HP:0000010","label":"Recurrent urinary tract infections","primary":false},{"hpoId":"HP:0035005","label":"Reduced hepatic alanine-glyoxylate aminotransferase activity","primary":false},{"hpoId":"HP:0000083","label":"Renal insufficiency","primary":false},{"hpoId":"HP:0030507","label":"Retinal crystals","primary":false},{"hpoId":"HP:0000488","label":"Retinopathy","primary":false},{"hpoId":"HP:0003774","label":"Stage 5 chronic kidney disease","primary":false},{"hpoId":"HP:0001297","label":"Stroke","primary":false}],"ledeHtml":"Primary hyperoxaluria type 1 (PH1) is caused by deficiency of the liver peroxisomal enzyme alanine-glyoxylate aminotransferase (AGT), which catalyzes the conversion of glyoxylate to glycine. When AGT activity is reduced or absent, glyoxylate is converted to oxalate, which cannot be metabolized and must be excreted by the kidneys. Insoluble calcium oxalate crystals form due to high urinary oxalate concentration. Urinary crystals aggregate, leading to nephrolithiasis (i.e., calcium oxalate kidney stones) in the renal pelvis / urinary tract; often the crystals deposit in kidney parenchyma (nephrocalcinosis). The age at presentation of PH1 ranges from infancy (age &lt;12 months) in 10% of individuals, childhood/adolescence (age 1-17 years) in 70%, and adulthood (age ≥18 years) in 20%.","mondoId":"MONDO:0009823","node":{"canonicalSlug":"primary-hyperoxaluria-type-1","comparisons":[{"documentSha256":"a2a7d827df34eec092c1978bdaaa6a1343640ce71917c0030b55effa61abdd5f","key":"legacy-primary-hyperoxaluria-type-1","kind":"legacy","label":"primary hyperoxaluria type 1","memberIds":["MONDO:0009823"],"mondoId":"MONDO:0009823","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/primary-hyperoxaluria-type-1.a2a7d827df34eec092c1978bdaaa6a1343640ce71917c0030b55effa61abdd5f.json"},{"documentSha256":"154b805a82b66671d7fe404fae2eef490c2a51bb1d56920205679a4096052bd3","key":"expanded-primary-hyperoxaluria","kind":"expanded","label":"primary hyperoxaluria","memberIds":["MONDO:0002474","MONDO:0009823","MONDO:0009824","MONDO:0013327"],"mondoId":"MONDO:0002474","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/node-comparison-154b805a82b66671d7fe.154b805a82b66671d7fe404fae2eef490c2a51bb1d56920205679a4096052bd3.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"summary","matchMethod":"automatic-preferred-title","name":"Primary Hyperoxaluria Type 1","paragraphs":["Primary hyperoxaluria type 1 (PH1) is caused by deficiency of the liver peroxisomal enzyme alanine-glyoxylate aminotransferase (AGT), which catalyzes the conversion of glyoxylate to glycine. When AGT activity is reduced or absent, glyoxylate is converted to oxalate, which cannot be metabolized and must be excreted by the kidneys. Insoluble calcium oxalate crystals form due to high urinary oxalate concentration. Urinary crystals aggregate, leading to nephrolithiasis (i.e., calcium oxalate kidney stones) in the renal pelvis / urinary tract; often the crystals deposit in kidney parenchyma (nephrocalcinosis). The age at presentation of PH1 ranges from infancy (age <12 months) in 10% of individuals, childhood/adolescence (age 1-17 years) in 70%, and adulthood (age ≥18 years) in 20%.","The natural history of untreated PH1 is (1) progressive decline in kidney function due to complications of nephrolithiasis (e.g., urinary obstruction, infection) and nephrocalcinosis, and (2) in persons with advanced chronic kidney disease (CKD), high plasma oxalate concentrations result in other organ and tissue damage from calcium oxalate deposition (i.e., \"oxalosis\"), most commonly in the bones, heart, and retina. In the absence of treatment, progression of oxalosis results in death from kidney failure and/or other organ involvement."],"reviewed":"2025-12-11","scope":"exact","source":"GeneReviews","sourceExcerpt":"Summary / Clinical characteristics","sourceRelease":"2026-10-18 12:11:33.001328+00","upstream":"GeneReviews clinical characteristics","url":"https://www.ncbi.nlm.nih.gov/books/NBK1283/"},"ownColumnKeys":["population-3e6e625bf703e1b61d68","population-c20c6a38a305a04a30df"],"publication":"published","relationships":[{"kind":"parent","label":"primary hyperoxaluria","mondoId":"MONDO:0002474","slug":"primary-hyperoxaluria"},{"kind":"parent","label":"alanine glyoxylate aminotransferase deficiency","mondoId":"MONDO:0100278","slug":"alanine-glyoxylate-aminotransferase-deficiency"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[{"reason":"Name scope not exact or reviewed","source":"GARD","url":"https://rarediseases.info.nih.gov/diseases/2835"}],"translation":"pending"},"records":[{"frequencyKind":"count","key":"054900db6436cd10c935486ef3df88287fa0a978d386bfd20c8ae71ca1ab174d","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0001944","is_excluded":false,"label":"Dehydration","onset_id":null,"reference":"PMID:9643991","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"07af6f00904a261712fcde80c2103eeee0baf8f8aa4ef501201429a4cb810b09","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0035005","is_excluded":false,"label":"Reduced hepatic alanine-glyoxylate aminotransferase activity","onset_id":null,"reference":"PMID:2880111","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"0ee4816ffc07ff368cc4c246b15ed1584a775f2c60fa8d8616bfac3f25e47569","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0001942","is_excluded":false,"label":"Metabolic acidosis","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"1e62f7397bd9dcc044d8a807abae482d7bc68101763a7e47d462c3c039cacd21","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0000121","is_excluded":false,"label":"Nephrocalcinosis","onset_id":null,"reference":"PMID:9643991","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"23aba4817b7b2a1bb073c7515da2e09c6d04778c9d635c4f492a596528d2215d","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0012213","is_excluded":false,"label":"Decreased glomerular filtration rate","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"39ef4fc0468c290acf363b10bd0fc8cd71bebac286c1038c7292cfa070eb8773","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0004417","is_excluded":false,"label":"Intermittent claudication","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"3a0f00099324a590e33d3dbdcbc21e73bc2479dec910b90db010731ffbcbfd45","raw":{"aspect":"P","body_system":"head_and_neck","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040284","hpo_id":"HP:0000164","is_excluded":false,"label":"Abnormality of the dentition","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"41c4033310c5c5b17009973bf0c2c4e536ec28b397b4eb4b159905df88fdf256","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002756","is_excluded":false,"label":"Pathologic fracture","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"4d4044a3ba47aba89d64f8d3cd87f6f98cc4b4cd97a4af8740124c19aa9ca135","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000790","is_excluded":false,"label":"Hematuria","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"4d6cea65fdb43ea4570103186e5ead118c565d81a5e032d9379d7137064b2171","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040284","hpo_id":"HP:0001297","is_excluded":false,"label":"Stroke","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"4f8a154ee605a97085b3d150d3a7a814af1321173fce70e69af64d6c524e9d64","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0003761","is_excluded":false,"label":"Calcinosis","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"5482e2946aa410ffae8b12c6416dacab0aa1f65200d183a3f39f3b96d75ea285","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0009830","is_excluded":false,"label":"Peripheral neuropathy","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"5936aa488f9fed457e56aa3004875c972fe721c756e98bb8895a064a0dd53c46","raw":{"aspect":"P","body_system":"growth","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001508","is_excluded":false,"label":"Failure to thrive","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"5c9f7257faac96eaffe0351e9461f3698fa95df9dc2357085735e6c232f7a304","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0100518","is_excluded":false,"label":"Dysuria","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"5cd6562400518022108d9070cee1d4c9958e4d5518a348ce0bc66dabe463b198","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001138","is_excluded":false,"label":"Optic neuropathy","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"678188c53461305c1af87c432fcd12fb98562207f784f4c4c8ecbcbc59a930c8","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0011021","is_excluded":false,"label":"Abnormal circulating enzyme concentration","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"67a866e72944b963e62a2fc0717197009c6508344d1505e707a500738e029e07","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0030507","is_excluded":false,"label":"Retinal crystals","onset_id":null,"reference":"PMID:23666469","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"75628f5bc7bcae99e72a882046e6de45aaf98934c3cb02459b616a3334bf06fc","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000010","is_excluded":false,"label":"Recurrent urinary tract infections","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"77a4e41c312866a5f6645517a9024ae0e5969efe8176643260235d549cb024f5","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000805","is_excluded":false,"label":"Enuresis","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"80ba6148cba3ed9c0a39a5e529a0b497bd90cc65fd32c9b9929754e0e0c4047c","raw":{"aspect":"P","body_system":"skin","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0001063","is_excluded":false,"label":"Acrocyanosis","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"8a3fb56b34ed61c50033d41f4358d2ff13df9815d4187aa8bbf82f5f0d48dae5","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000787","is_excluded":false,"label":"Kidney stone","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"938f83c8d28a370baac39bae1bc815c7436f2eebad2bf1bca10a828939509125","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0003159","is_excluded":false,"label":"Hyperoxaluria","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"94097ce1b89b89019ab09ec423819e9da27ea08cfcf56476eb78c56f8e3e38de","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0001678","is_excluded":false,"label":"Atrioventricular block","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"9a32a06948e0f9158aa6b30c4d22841b15c483eab6bcb8956fb38e2333995349","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0002653","is_excluded":false,"label":"Bone pain","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"9c7743e0ad239784bf7dff7f5579d29ecb8329ff587808268aac6ad3cd8c94fe","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0003159","is_excluded":false,"label":"Hyperoxaluria","onset_id":null,"reference":"PMID:9643991","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"a37d1e2e85f4e0d9f255e13c6cc888525baea20b939da68635f114b4bfb520a3","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001942","is_excluded":false,"label":"Metabolic acidosis","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"ab79f110d18c2e722e1f2a6f1776c220bc1dd5f807ecdb9bbdb67a40cd1f3bc8","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000965","is_excluded":false,"label":"Cutis marmorata","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"bcf4ff6d9d6189ae5af4d4f02be527d876f9c198d657d4734f94829f139a32f6","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040284","hpo_id":"HP:0002621","is_excluded":false,"label":"Atherosclerosis","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"c94d7200dd54fcc293965121dfb1613de325a39b40797dfc2be8541360b9e88d","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0000488","is_excluded":false,"label":"Retinopathy","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"ccf55bc357db621ab9e761d8f5aa511ac18a44d63ed0c8661228ef9f218a01bf","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0004950","is_excluded":false,"label":"Peripheral arterial stenosis","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"cfaa1e7f3da8f46d5155ab7884acde746c1fb3fb341f4997241244f7d35d3ec2","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0011001","is_excluded":false,"label":"Increased bone mineral density","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"d3c909b0dbe58e880bed7f6808297de19ade9c70b22a383faa787e55cf853696","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0025324","is_excluded":false,"label":"Arterial occlusion","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"d3db3b8e946bb368b403c3e1a655a1589befd49c1c620212767e6ddeacce38c9","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:6000431","is_excluded":false,"label":"Elevated urinary glycolic acid level","onset_id":null,"reference":"PMID:4701948","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"d3ee045c75afcee13dd1b0676171034e8dd29cb5dd804e1f05813049e142b9a9","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0000790","is_excluded":false,"label":"Hematuria","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"d78fe3b713672c7971b030801e5e3072bbfa180f4915b613f91c3de773f5b477","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000121","is_excluded":false,"label":"Nephrocalcinosis","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"d7f11fb7a8e737c6589b066b5ab7d8e5735fbedef3768932b18c183a287f82a9","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0000083","is_excluded":false,"label":"Renal insufficiency","onset_id":null,"reference":"PMID:9643991","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"da2e0544db03cc3f4d4b0eebab26303d2e068ce298f1270247b25e7f36e14651","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0025520","is_excluded":false,"label":"Calcinosis cutis","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"daa42829d012fd35ba4d3c7bbaec04dc283c9abc21addac74d19e72b1a60bb43","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0003774","is_excluded":false,"label":"Stage 5 chronic kidney disease","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"e25e722c40fefe8c70b05725c64f70acceb0508489c3f0a9c4c9bb62b639a317","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0011506","is_excluded":false,"label":"Choroidal neovascularization","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"e46f6286d15916ab71916c327bd692f08b32d33f4a8998de334ee5d1cf47019d","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040284","hpo_id":"HP:0001939","is_excluded":false,"label":"Abnormality of metabolism/homeostasis","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"e509a7adb7216565fac334d760d939876a400933c4f29d91f6a137d1161551f3","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0008672","is_excluded":false,"label":"Calcium oxalate nephrolithiasis","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"e837a9340b2583e869505a0dbd8725eed04c0d8bf2b26defe0df66a65af39893","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0030880","is_excluded":false,"label":"Raynaud phenomenon","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"ea952d01b08fcf2bf9bac8e9b40da2692ec425b37cf72531715daaa6f8e75568","raw":{"aspect":"P","body_system":"other","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0100758","is_excluded":false,"label":"Gangrene","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"edf6f03dd51a8a850b0a92b88a37885ef0f132713d1000b7a9c5742f8ca8310e","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:6000702","is_excluded":false,"label":"Elevated urinary glyoxylic acid level","onset_id":null,"reference":"PMID:449695","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"eeadf09b54ef2493d1140a56b660ceb168f10d0cc7ce746f1a47a7123be977cf","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:259900","disease_name":"Hyperoxaluria, primary, type I","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0000648","is_excluded":false,"label":"Optic atrophy","onset_id":null,"reference":"OMIM:259900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"f9c1ab898489b8d994eb1652606496e6724b26efd850e1056a0243483216b2e5","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001903","is_excluded":false,"label":"Anemia","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"fac1aa3ad7b4a11d6fa545c2cb7a9d19b0aed29795edcc9c27d93618f313b746","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:93598","disease_name":"Primary hyperoxaluria type 1","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000924","is_excluded":false,"label":"Abnormality of the skeletal system","onset_id":null,"reference":"ORPHA:93598","source_release":"2026-06-23"},"sourceGroups":["orphanet"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK1283/\" rel=\"noreferrer\">GeneReviews</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0009823\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-preferred-title</dd><dt>Upstream attribution</dt><dd>GeneReviews clinical characteristics</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Primary hyperoxaluria type 1 (PH1) is caused by deficiency of the liver peroxisomal enzyme alanine-glyoxylate aminotransferase (AGT), which catalyzes the conversion of glyoxylate to glycine. When AGT activity is reduced or absent, glyoxylate is converted to oxalate, which cannot be metabolized and must be excreted by the kidneys. Insoluble calcium oxalate crystals form due to high urinary oxalate concentration. Urinary crystals aggregate, leading to nephrolithiasis (i.e., calcium oxalate kidney stones) in the renal pelvis / urinary tract; often the crystals deposit in kidney parenchyma (nephrocalcinosis). The age at presentation of PH1 ranges from infancy (age &lt;12 months) in 10% of individuals, childhood/adolescence (age 1-17 years) in 70%, and adulthood (age ≥18 years) in 20%.</p><p>The natural history of untreated PH1 is (1) progressive decline in kidney function due to complications of nephrolithiasis (e.g., urinary obstruction, infection) and nephrocalcinosis, and (2) in persons with advanced chronic kidney disease (CKD), high plasma oxalate concentrations result in other organ and tissue damage from calcium oxalate deposition (i.e., &quot;oxalosis&quot;), most commonly in the bones, heart, and retina. In the absence of treatment, progression of oxalosis results in death from kidney failure and/or other organ involvement.</p><p class=\"section-source\">Source: <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK1283/\" rel=\"noreferrer\">GeneReviews</a></p>","key":"overview","title":"Overview"}],"sharedSources":[],"slug":"primary-hyperoxaluria-type-1","sourceDocuments":[{"name":"GeneReviews: Primary Hyperoxaluria Type 1","reviewed":"2025-12-11","source_release":"2026-10-18 12:11:33.001328+00","url":"https://www.ncbi.nlm.nih.gov/books/NBK1283/"},{"name":"MONDO: primary hyperoxaluria type 1","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0009823"}],"sourceNote":"","synonyms":["AGXT primary hyperoxaluria","glycolic aciduria","HP1","hyperoxaluria, primary, type I","peroxisomal alanine glyoxylate aminotransferase deficiency","peroxisomal alanine-glyoxylate aminotransferase deficiency","PH1","primary hyperoxaluria caused by mutation in AGXT","primary hyperoxaluria type 1","primary hyperoxaluria type I","serine pyruvate aminotransferase deficiency"],"takeawayHtml":"","title":"primary hyperoxaluria type 1"},"schemaVersion":1}
